

## RESEARCH ARTICLE

[View Article Online](#)  
[View Journal](#) | [View Issue](#)Cite this: *RSC Med. Chem.*, 2024, 15, 2160Received 24th January 2024,  
Accepted 14th May 2024

DOI: 10.1039/d4md00070f

[rsc.li/medchem](https://rsc.li/medchem)Synergy between the clavanins as a weapon against multidrug-resistant *Enterobacter cloacae*†Marvin D. Naing, <sup>a</sup> Samuel A. Juliano<sup>a</sup> and Alfredo M. Angeles-Boza <sup>\*ab</sup>

Finding new antibiotics that can act synergistically with each other offers many benefits such as lower dosages used for each drug, improved pathogen clearance, and ability to act against multi-drug resistant strains. In this study, six peptides isolated from the tunicate *Styela clava* were evaluated for their synergistic interaction using the checkerboard assay and the time kill kinetics assay. Using two different tests, we report synergy between clavanin D and clavaspurin in both tests and synergy between clavanin A and B only in the checkerboard test when used against the multidrug resistant *E. cloacae* 0136. This work demonstrates the possible cooperativity between homologous AMPs from a single organism and the advantage of using two susceptibility tests instead of one when testing synergistic combinations.

As predicted by Alexander Fleming, we have misused antibiotics and we now find ourselves facing an increasing prevalence of antibiotic-resistant bacteria. This social dilemma, known as antibiotic resistance, is a global threat.<sup>1,2</sup> To overcome this problem, we and many other groups are developing new antimicrobials and therapies that will eventually replace our current arsenal to better fight off superbugs in the future.<sup>3–6</sup>

The recent emergence of *Enterobacter cloacae* strains resistant to broad-spectrum antibiotics, including the last-resort carbapenems, has caused increased interest in finding therapies against this group of microorganisms. The *E. cloacae* complex contains common human pathogens that cause a wide variety of infections. Further, being a Gram-negative pathogen, the double membrane structure with the outer membrane containing lipopolysaccharide and lipid A makes it harder for many antimicrobial agents to penetrate.<sup>7</sup>

Antimicrobial peptides (AMPs) continue to be a promising avenue for antimicrobial drug discovery and development because of their broad-spectrum activity encompassing bacteria, fungi, viruses, and unicellular protozoa.<sup>8,9</sup> Various organisms produce multiple AMPs with high homology as part of their innate immune defense; however, the benefits of just a few mutations in their sequence are unknown. The clavanin family of AMPs, found in the hemocytes of the tunicate *Styela clava*,<sup>10</sup> consists of six peptides (Table 1). Five of them have *ca.* 80% sequence similarity whereas the sixth

member only possess ~30% sequence similarity to ClavA, the archetypical member of this family.<sup>11</sup> Since their discovery, the clavanins, particularly ClavA, have been shown to possess potent antimicrobial activity against several Gram-positive and Gram-negative bacteria as well as some fungi.<sup>10,12–19</sup> It is generally assumed that the other clavanins would follow the same mechanism of action (MoA) as ClavA but this doesn't rationalize why the tunicate would spend resources to produce multiple similar peptides with the same MoA. We hypothesize that one of the reasons for the production of these multiple homologues is a synergistic activity among the peptides produced. More importantly, we could take advantage of this synergistic behavior to develop therapies to combat nosocomial pathogens.

In this study, we identify synergistic pairs among the clavanins that are active against the Gram-negative ESKAPE pathogen, *E. cloacae* (CDC AR isolate bank #0136).<sup>21</sup> We employed the checkerboard assay to spot the synergistic pairs that can combat *E. cloacae* under acidic conditions. The time-kill kinetics assay is then used to further confirm the synergy among the pairs. Having both tests agree with each other means that there is undeniable synergy among the pair.<sup>22</sup>

All members of the clavanin family were synthesized using solid-phase peptide synthesis, purified and characterized according to published protocols (Fig. S1–S6†). The sequences of the peptides are shown in Table 1. These peptides are cationic,  $\alpha$ -helical (Fig. 1), amphipathic, and are rich in histidine and phenylalanine residues. Clavanin A and B are the most similar pair, with only a K to R mutation at position 7. Clavanin C and D are the only ones that contain a L-DOPA residue in place of Y15.<sup>14</sup> Using a standard broth microdilution assay in MHB media, the minimum inhibitory concentration (MIC) of the clavanins against *E. cloacae* 0136,

<sup>a</sup> Department of Chemistry, University of Connecticut, Storrs 06269, USA.E-mail: [alfredo.angeles-boza@uconn.edu](mailto:alfredo.angeles-boza@uconn.edu)<sup>b</sup> Institute of Materials Science, University of Connecticut, Storrs 06269, USA† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4md00070f>

**Table 1** MIC data for the clavanins obtained using the broth microdilution assay against *E. cloacae* AR# 0136 and their percent helicity calculated from CD spectroscopy data

Peptide	Abbr.	Sequence	MIC, $\mu\text{M}$ ( $\mu\text{g mL}^{-1}$ )		% helicity <sup>20</sup>
			pH 5.5	pH 7.4	
Clavanin A	ClavA	VFQFL GKIIH HVGNF VHGFH HVF-NH <sub>2</sub>	>128 (341)	>128 (341)	50.1
Clavanin B	ClavB	VFQFL GRIIH HVGNF VHGFH HVF-NH <sub>2</sub>	128 (344)	>128 (344)	45.1
Clavanin C	ClavC	VFHLL GKIIH HVGNF VY'GFS HVF-NH <sub>2</sub>	16 (46)	>128 (372)	36.3
Clavanin D	ClavD	AFKLL GRIIH HVGNF VY'GFS HVF-NH <sub>2</sub>	8 (23)	>128 (371)	21.6
Clavanin E	ClavE	LFKLL GKIIH HVGNF VHGFH HVF-NH <sub>2</sub>	8 (23)	>128 (368)	49.0
Clavaspirin	ClavS	FLRFI GSVIH GIGHL VHHIG VAL-NH <sub>2</sub>	4 (11)	128 (348)	39.8
Magainin 2	Mag2	GIGKF LHSAG KFGKA FVGEI MNS-NH <sub>2</sub>	4 (4.9)	4 (4.9)	—

Y' = DOPA residue.<sup>14</sup>

were determined at two different pH values: 5.5 and 7.4. This bacterial strain is resistant to a number of antibiotic classes such as aminoglycosides,  $\beta$ -lactams, sulfonamides, and trimethoprim.<sup>21</sup> Table 1 summarizes the results with Magainin2, a pore-forming cationic AMP, used as a control.<sup>13</sup> We tested all the peptides at a maximum concentration of 128  $\mu\text{M}$  because higher concentrations lead to precipitation of the peptides when mixed in MHB media. To our knowledge, this is the first report on the activity of the clavanins against *E. cloacae*.


From the above data, the clavanins have higher activity at pH 5.5 than at pH 7.4, confirming previous reports on ClavA and ClavS.<sup>11,13</sup> This is attributed to the multiple histidine residues in their sequence that get protonated at lower pH, making it more cationic and thus increasing the affinity towards the negatively charged microbial membrane. In *S. clava*, the vacuoles of phagocytic hemocytes, where the clavanins are found, undergo acidification as part of the process to eliminate the phagocytosed organisms.<sup>12</sup> Recent reports suggest that *E. cloacae* can survive inside the acidic lysosomal environment of macrophages after disrupting normal phagocytic trafficking.<sup>23</sup> Succeeding experiments were performed at pH 5.5 based on these results.

We used two methodologies to determine synergy among clavanins. The first method is the checkerboard assay which involves the calculation of the fractional inhibitory concentration (FIC, ESI† eqn (S2)) from the observed MICs

alone and in combination.<sup>24</sup> One downside of this method is that it is not capable of testing more than two drugs at one time and it only measures one endpoint with either a growth or no growth reading within the experimental time frame.<sup>25</sup> The way the FIC is calculated is similar to the Loewe additivity model (ESI† eqn (S3)) of synergy and the isobologram analysis, both of which operate under the assumption that a compound cannot interact with itself and two different compounds that have the same effect are equivalent or additive.<sup>26,27</sup> The second method is the time-kill kinetics assay which measures changes in bacterial titer over time.<sup>25</sup> Both methods are based on the Clinical and Laboratory Standards Institute (CLSI) guidelines.<sup>25,28</sup> To offer a more pragmatic way of testing, the concentrations that had the lowest FIC from the checkerboard assay was the one used in the time-kill assay. This assay also has a different criterion for pronouncing synergy. A deviation of  $\geq 2$  log decrease in CFU mL<sup>-1</sup> is considered synergistic.<sup>22</sup> This is similar to what the Bliss independence model implies (ESI† eqn (S5)). There is strong synergy if the combination is synergistic in both tests and a weak synergy if only synergistic in one test. Having two methodologies that operate under two different synergy models would allow us to gauge the strength of the synergy observed between the clavanins as well as attain a more consistent synergy result.

Despite the similarities in the amino acid sequence and activity of the clavanins, there is marked difference in terms of their pair-wise activity (Fig. 2, ESI† Table S1). The results from the checkerboard assay and the isobologram analysis show that only two pairs are synergistic against *E. cloacae* 0136, namely, ClavA + ClavB and ClavD + ClavS. One pair, ClavE + ClavS, has an additive interaction. The rest of the combinations have no effect or are indifferent from each other. No pair resulted in an antagonistic interaction.

We then performed the time-kill kinetics assay on the two synergistic pairs reported above. The combination of ClavD and ClavS is synergistic (Fig. 3) based on the criteria mentioned above. The ClavA and B pair, which shows a bacteriostatic response, is not deemed synergistic using this assay since the difference between the response of the most active component and the actual response of the combination is only about 1.5 log decrease in CFU.

**Fig. 1** CD spectroscopy data for all the clavanins taken at 50  $\mu\text{M}$  concentration in 50% TFE solution showing the typical  $\alpha$ -helix signals.




Fig. 2 Isobolograms for all possible pairs of the clavans. The dashed line illustrates the model additive interaction expected for Loewe additivity. The lowest FIC is listed at the top of each isobologram. Synergy is defined as having an FIC of  $\leq 0.5$  which is only seen in the combination of Clav A + B and Clav D and S.

Nonetheless, the deviation implies that the two peptides are interacting albeit a weaker response. The high sequence similarity for ClavA and B, which differ in only one amino

acid, could be the reason for this weak synergy. Both amino acids, K and R, are basic and would carry a positive charge under these conditions. This may be the reason why they behave similarly at the concentration tested, both individually and in combination. The difference between ClavA and ClavB could lie in their ability to penetrate the membrane because Arg residues are known to insert themselves in lipid membranes better than Lys residues resulting to an increased cellular penetration.<sup>29</sup>

The results of the checkerboard assay and the time-kill assay confirmed synergy between ClavD and ClavS warranting further mechanistic investigation. We performed confocal microscopy studies on ClavD and ClavS to get insight on their behavior and interaction in the presence of cells. Both ClavD and ClavS were tagged with either 5(6)-carboxytetramethylrhodamine (TAMRA) or 5(6)-carboxyfluorescein (FAM) by substituting a phenylalanine residue (F2 and F4 in ClavD and ClavS, respectively) with a lysine protected by a 4-methyltrityl (Mtt) group as shown in Scheme S1.† The replacement of a hydrophobic residue with a hydrophobic dye would have the least impact on the activity of the peptides, an approach we have followed in the past.<sup>30,31</sup> After tagging the peptides, their MICs were assessed to make sure that the dye did not affect their antimicrobial activity. The susceptibility assay showed that the MICs of the tagged peptides were the same as those of the untagged peptides. A checkerboard assay confirmed that the ClavD-FAM and ClavS-TAMRA are synergistic and this verifies a previous report stating that common fluorescent probes have minimal to no effect on the antimicrobial activity of AMPs.<sup>32</sup> When *E. cloacae* cells were incubated for 30 min with either





Fig. 3 Time-kill kinetics curve of synergistic clavane pairs against *E. cloacae* 0136. Each peptide was tested at the concentration that gave the lowest FIC in the checkerboard assay. ClavA and B were tested at 16  $\mu\text{M}$  each, while ClavD and ClavS were tested at 2 and 1  $\mu\text{M}$ , respectively.







**Fig. 4** Confocal microscopy images of *E. cloacae* treated with (A) ClavD-FAM, (B) ClavS-TAMRA, and (C) combined treatment of ClavD-FAM and ClavS-TAMRA. Bacteria were incubated with the peptides for 30 min before mounting on glass slides. Images were taken using Nikon A1R confocal microscope with 60 $\times$  oil immersion objective (scale bars = 5  $\mu$ m).


ClavD-FAM and ClavS-TAMRA, we observed full translocation of the peptides, suggesting that there is an internal target for the peptides (Fig. 4A and B). In the combined treatment (Fig. 4C), the majority of the bacterial cells have both peptides inside the cells whereas only a small number have ClavS-TAMRA localized on the cell membrane. This is in contrast to the cells treated with ClavS-TAMRA only (*vide*

*supra*). In all cases, there was no evidence of membrane damage.

Lack of membrane damage was also observed in transmission electron microscopy (TEM) experiments done on *E. cloacae* 0136 treated with ClavD + ClavS (Fig. 5). Cells treated with the ClavD + ClavS combination show internal damage while keeping the membrane intact (no blisters or protruding bubbles/blebs). Regions of low electron density on some of the cells can be observed which accounts for intracellular damage similar to what was reported for *rhizobium* strains treated with polymyxin B.<sup>33</sup> Some cells contained black spots (very electron-dense areas) which can be evidence for aggregated intracellular components as a result of the exposure to both peptides. This is also similar to what was observed with colistin-treated *E. coli*.<sup>34</sup>

Our evidence indicates that the synergistic pair does not act primarily on membrane disruption but on an intracellular target. To our knowledge, this is the first reported synergistic interaction between two AMPs of this type. There are several examples in the literature on synergy between AMPs but there is no universal agreement on the molecular characteristics of peptides that lead to synergy.<sup>35</sup> For example, abaecin, an AMP that is suspected of targeting the molecular chaperone DnaK, synergizes with hymenoptaecin, a pore-forming AMP.<sup>9</sup> In this case, hymenoptaecin opens up pores in the bacterial membrane which facilitate easier entry for abaecin and provide easy access to internal targets. Similarly, the less active AMPs from the winter flounder, such as WF3, are able to control the membrane interactions of the more active winter flounder AMPs, such as pleurocidin, resulting to a potentiated activity at much lower concentrations.<sup>36</sup> Combinations that don't have this type of cooperativity are also possible. For example, magainin and PGLa demonstrated synergy by forming defined supramolecular structures along the membrane surface that leads to increased permeabilization and eventually, cell death.<sup>37,38</sup>

In summary, the criteria used in this study utilizing both checkerboard and time-kill kinetics assays for two different synergy models, identified two new synergistic AMP pairs that are active against the MDR strain *E. cloacae* 0136. This indicates cooperativity between AMPs produced by a single organism. ClavA and ClavB, together, are bacteriostatic against *E. cloacae*. Against this problematic pathogen, the combination of ClavD and ClavS is bactericidal and provides a promising avenue for the development of novel therapies, although we still need to identify the specific target(s) of such a synergistic pair. Confocal microscopy and TEM results suggest that both ClavD and ClavS can translocate inside the cells without damaging the membrane (ESI† video). This suggests that the MOA is intracellular and that these peptides can interfere with processes inside the bacterial cell. Future studies will focus on establishing the targets of this synergistic pair.



**Fig. 5** TEM images of *E. cloacae*. Top images represent untreated cells (OM = outer membrane, PS = periplasmic space, IM = internal membrane, N = nucleoid). Bottom images represent cells treated with 1  $\mu$ M ClavD and 0.5  $\mu$ M ClavS showing electron-lucent region (red circle) and electron-dense regions (red arrows). Scale bars = 200 nm.



## Author contributions

S. A. J.: conceptualization, investigation, and data curation. M. D. N.: conceptualization, data curation, investigation, writing – review and editing. A. M. A.-B., conceptualization, funding acquisition, supervision, writing – review and editing. This work was supported by the National Science Foundation through MCB1715494 to A. M. A.-B.

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- 1 S. S. Kadri, *Crit. Care Med.*, 2020, **48**, 939.
- 2 Centers for Disease Control and Prevention (U.S.), *Antibiotic resistance threats in the United States, 2019*, Centers for Disease Control and Prevention (U.S.), 2019.
- 3 J. Portelinha and A. M. Angeles-Boza, *ChemBioChem*, 2021, **22**, 1646–1655.
- 4 J. Portelinha, S. S. Duay, S. I. Yu, K. Heilemann, M. D. J. Libardo, S. A. Juliano, J. L. Klassen and A. M. Angeles-Boza, *Chem. Rev.*, 2021, **121**, 2648–2712.
- 5 T. Misawa, C. Goto, N. Shibata, M. Hirano, Y. Kikuchi, M. Naito and Y. Demizu, *MedChemComm*, 2019, **10**, 896–900.
- 6 D. Ben Hur, G. Kapach, N. A. Wani, E. Kiper, M. Ashkenazi, G. Smollan, N. Keller, O. Efrati and Y. Shai, *J. Med. Chem.*, 2022, **65**, 9050–9062.
- 7 R. Jasim, M.-L. Han, Y. Zhu, X. Hu, M. Hussein, Y.-W. Lin, Q. Zhou, C. Dong, J. Li and T. Velkov, *Int. J. Mol. Sci.*, 2018, **19**, 2356.
- 8 M. Mahlapuu, J. Håkansson, L. Ringstad and C. Björn, *Front. Cell. Infect. Microbiol.*, 2016, **6**, 194.
- 9 L. Duong, S. P. Gross and A. Siryaporn, *Front. Med. Technol.*, 2021, **3**, 640981.
- 10 C. Zhao, L. Liaw, I. Hee Lee and R. I. Lehrer, *FEBS Lett.*, 1997, **410**, 490–492.
- 11 I.-H. In, C. Zhao, T. Nguyen, L. Menzel, A. J. Waring, R. I. Lehrer and M. A. Sherman, *J. Pept. Res.*, 2001, **58**, 445–456.
- 12 S. A. Juliano, S. Pierce, J. A. deMayo, M. J. Balunas and A. M. Angeles-Boza, *Biochemistry*, 2017, **56**, 1403–1414.
- 13 I. H. Lee, Y. Cho and R. I. Lehrer, *Infect. Immun.*, 1997, **65**, 2898–2903.
- 14 R. I. Lehrer, *Integr. Comp. Biol.*, 2003, **43**, 313–322.
- 15 E. J. M. van Kan, R. A. Demel, A. van der Bent and B. de Kruijff, *Biochim. Biophys. Acta, Biomembr.*, 2003, **1615**, 84–92.
- 16 E. J. M. van Kan, R. A. Demel, E. Breukink, A. van der Bent and B. de Kruijff, *Biochemistry*, 2002, **41**, 7529–7539.
- 17 E. J. M. van Kan, D. N. Ganchev, M. M. E. Snel, V. Chupin, A. van der Bent and B. de Kruijff, *Biochemistry*, 2003, **42**, 11366–11372.
- 18 S. A. Juliano, L. F. Serafim, S. S. Duay, M. Heredia Chavez, G. Sharma, M. Rooney, F. Comert, S. Pierce, A. Radulescu, M. L. Cotten, M. Mihailescu, E. R. May, A. I. Greenwood, R. Prabhakar and A. M. Angeles-Boza, *ACS Infect. Dis.*, 2020, **6**, 1250–1263.
- 19 O. N. Silva, E. S. F. Alves, C. de la Fuente-Núñez, S. M. Ribeiro, S. M. Mandal, D. Gaspar, A. S. Veiga, M. A. R. B. Castanho, C. A. S. Andrade, J. M. Nascimento, I. C. M. Fensterseifer, W. F. Porto, J. R. Correa, R. E. W. Hancock, S. Korpole, A. L. Oliveira, L. M. Liao and O. L. Franco, *Sci. Rep.*, 2016, **6**, 27128.
- 20 M. M. Juban, M. M. Javadpour and M. D. Barkley, in *Antibacterial Peptide Protocols*, Humana Press, New Jersey, 1997, vol. 78, pp. 73–78.
- 21 J. D. Lutgring, M.-J. Machado, F. H. Benahmed, P. Conville, R. M. Shawar, J. Patel and A. C. Brown, *J. Clin. Microbiol.*, 2018, **56**, e01415–e01417.
- 22 J. Tang, K. Wennerberg and T. Aittokallio, *Front. Pharmacol.*, 2015, **6**, 181.
- 23 G. Parau, F. Bisaro, H. Marshall and M. A. Valvano, *Access Microbiol.*, 2019, **1**, 227.
- 24 C. D. Doern, *J. Clin. Microbiol.*, 2014, **52**, 4124–4128.
- 25 *Antimicrobial Susceptibility Testing Protocols*, ed. R. Schwalbe, L. Steele-Moore and A. C. Goodwin, CRC Press, Boca Raton, 2007.
- 26 S. Lederer, T. M. H. Dijkstra and T. Heskes, *Front. Pharmacol.*, 2018, **9**, 31.
- 27 R. Huang, L. Pei, Q. Liu, S. Chen, H. Dou, G. Shu, Z. Yuan, J. Lin, G. Peng, W. Zhang and H. Fu, *Front. Pharmacol.*, 2019, DOI: [10.3389/fphar.2019.01222](https://doi.org/10.3389/fphar.2019.01222).
- 28 M07: Dilution AST for Aerobically Grown Bacteria - CLSI, <https://clsi.org/standards/products/microbiology/documents/m07/>, (accessed February 20, 2024).
- 29 L. Li, I. Vorobyov and T. W. Allen, *J. Phys. Chem. B*, 2013, **117**, 11906–11920.
- 30 M. D. J. Libardo, C. de la Fuente-Núñez, K. Anand, G. Krishnamoorthy, P. Kaiser, S. C. Pringle, C. Dietz, S. Pierce, M. B. Smith, A. Barczak, S. H. E. Kaufmann, A. Singh and A. M. Angeles-Boza, *ACS Infect. Dis.*, 2018, **4**, 1623–1634.
- 31 M. D. J. Libardo, V. Y. Gorbatyuk and A. M. Angeles-Boza, *ACS Infect. Dis.*, 2016, **2**, 71–81.
- 32 C. Zhao, A. Fernandez, N. Avlonitis, G. Vande Velde, M. Bradley, N. D. Read and M. Vendrell, *ACS Comb. Sci.*, 2016, **18**, 689–696.
- 33 I. Komaniecka, K. Zamłyńska, R. Zan, M. Staszczak, J. Pawelec, I. Seta and A. Choma, *Acta Biochim. Pol.*, 2016, **63**, 517–525.
- 34 N. Hazime, Y. Belguesmia, I. Kempf, A. Barras, D. Drider and R. Boukherroub, *Pharmaceuticals*, 2022, **15**, 682.
- 35 J. He, C. G. Starr and W. C. Wimley, *Biochim. Biophys. Acta, Biomembr.*, 2015, **1848**, 8–15.
- 36 M. Clarke, C. K. Hind, P. M. Ferguson, G. Manzo, B. Mistry, B. Yue, J. Romanopulos, M. Clifford, T. T. Bui, A. F. Drake, C. D. Lorenz, J. M. Sutton and A. J. Mason, *npj Antimicrob. Resist.*, 2023, **1**, 1–16.
- 37 E. Han and H. Lee, *RSC Adv.*, 2015, **5**, 2047–2055.
- 38 C. Aisenbrey, M. Amaro, P. Pospíšil, M. Hof and B. Bechinger, *Sci. Rep.*, 2020, **10**, 11652.

